Dynamk Capital
Venture capitalNew York · Seed–Series B · 4 people tracked
Investment thesis
Dynamk Capital invests in growth equity and venture capital stages in life sciences and industrial companies. The firm focuses on companies providing technologies, tools, and services for biopharmaceutical discovery, development, and manufacturing, including cell and gene therapies and vaccines.
Source: firm website, verified Aug 3, 2026.
Team · 4 people
from curated & public directories
What they invest in
from 11 of 14 portfolio companiesBiotech ×11Medical Devices ×5AI & Machine Learning ×3Deep Tech ×3Hardware ×3Healthtech ×3Advanced Manufacturing ×2
HQs:United States×4United Kingdom×1
Investments · 14 tracked
founders shown can be your intro pathBy year:2021 · 12017 · 12 dated
Develops analytical testing devices that minimize sample volume requirements for particle count determination in biopharmaceutical analysis.
bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.
BiotechDeep TechHealthtechMedical Devices
Dr Mark Kotter(Founder)Przemek Obloj(CEO)Emma Pepperellin
Co-investorsForesite CapitalBlueYard CapitalARCH Venture PartnersGood AI CapitalHAWKTAILMetaplanet+2 more
Xcell Biosciences develops the AVATAR platform, which integrates physiologic oxygen and pressure control into cell therapy R&D and GMP manufacturing workflows to condition cells for the tumor microenvironment.
BiotechHardwareHealthtech
Co-investorsAvego BioScience Capital
CellFE develops a microfluidic-based gene editing technology and a benchtop device for research and process development of cell therapies.
BiotechHardwareMedical Devices
Co-investorsCota CapitalGreatPoint VenturesM VenturesEmbark VenturesKhosla Ventures
Curi Bio provides a preclinical drug development platform combining 3D human tissue models of disease (cardiac and skeletal muscle), biosystems for functional analysis, and AI/ML-based insights to assess drug safety, efficacy, and potency.
AI & Machine LearningBiotechMedical Devices
Elliot Fisher(Cofounder)in
Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases.
AI & Machine LearningBiotechMedical DevicesNew York, US
Maria Pineda, PhD(CEO & Co-founder)Martin Akerman, PhD(CEO & Co-founder)Martin Akerman(Executive Officer, Director, Promoter)Maria Luisa Pineda(Executive Officer, Director, Promoter)Maria Luisa Pineda, PhD.(Founder)in
Co-investorsHAWKTAILM12 (Microsoft's Venture Fund)Madrona Venture GroupRed Cell IncubationDolby Family VenturesThird Kind Venture Capital
Lucid Scientific develops Resipher, a technology for live, continuous, and noninvasive monitoring of cellular oxygen consumption rate to study cell metabolism.
BiotechDeep TechHardwareAtlanta, US
Samuel Walker Inman(Executive Officer, Director)Ian W. Hunter(Executive Officer, Director)
BoardDr. Gustavo Mahler(Director)in
Co-investorsGRA Venture
Manufactures handheld cell culture monitors that measure oxygen consumption in multi-well plates for continuous real-time cell analysis.
A stem cell tools and technology company providing standardized platforms to accelerate regenerative medicine development and clinical trials.
BiotechFrederick, US
Jon Rowley(Director)Timothy Kelly(Executive Officer, Director)Margot Connor(Executive Officer, Director)Uplaksh Kumar(Chief Operating Officer)
BoardMartin Westberg(Director)Rob Carlson(Director)
Co-investorsMaryland TEDCOTEDCOVanedge CapitalVanedge Capital Limited PartnershipAvant Bio
Vernal Biosciences is a contract development and manufacturing organization (CDMO) offering mRNA and LNP-mRNA process development, GMP manufacturing, custom synthesis, and analytical testing.
Advanced ManufacturingBiotechColchester, US
Christian Cobaugh(Executive Officer, Director)Errik Anderson(Director)
Designs hardware and AI-driven software platforms for drug screening, primary cell analysis, and cell therapy manufacturing to enhance safety and performance.
Portfolio news
latest coverage across their companiesAlpenglow · startupfortune.com · May 10, 2026
Curi Bio · finsmes.com · Dec 3, 2025
CellFE · biotechmetro.com · Apr 19, 2025
Frequently asked questions
- How many investments has Dynamk Capital made?
- Dynamk Capital has 14 tracked investments.
- What stage does Dynamk Capital invest at?
- Dynamk Capital invests at the Seed, Series A, Series B stages.
- What sectors does Dynamk Capital focus on?
- Dynamk Capital focuses on Biotech, Medical Devices.
- Where is Dynamk Capital located?
- Dynamk Capital is headquartered in New York, US.
- Who does Dynamk Capital co-invest with?
- Dynamk Capital most often shares deals with ARCH Venture Partners, M12 (Microsoft's Venture Fund), Madrona Venture Group, among 17 tracked co-investors.
Co-investors · 1
Cota Capital is an investment firm focused on founders building net-new enterprise technology, combining capital with operational expertise, industry insight, competitive intelligence, and a broad network.
Firms observed investing alongside Dynamk Capital, from public investor directories. Shared companies are the overlap with Dynamk Capital's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.